Rumors continue to swirl that Amgen is in process of making an offer to buy Actelion. Analysts state that such a deal could be for as much as $9.8 B which would be the second largest European biotech deal ever behind Merck's acquisition of Serono for $10.3 B euros in 2007.
Amgen would acquire Actelion's drug Tracleer, for treatment of pulmonary arterial hypertension (PAH) which has patent life through 2015. Actelion has two additional PAH drugs in its current pipeline as replacement therapies. See Bloomberg for more.
Posted by Bruce Lehr November 18th 2010.